213 related articles for article (PubMed ID: 31906050)
1. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.
Debien V; Thouvenin J; Lindner V; Barthélémy P; Lang H; Flippot R; Malouf GG
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906050
[TBL] [Abstract][Full Text] [Related]
2. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma.
Hahn AW; Lebenthal J; Genovese G; Sircar K; Tannir NM; Msaouel P
Cancer Treat Res Commun; 2022; 33():100640. PubMed ID: 36174377
[TBL] [Abstract][Full Text] [Related]
3. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
Pichler R; Compérat E; Klatte T; Pichler M; Loidl W; Lusuardi L; Schmidinger M
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30934624
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Kiyozawa D; Takamatsu D; Kohashi K; Kinoshita F; Ishihara S; Toda Y; Eto M; Oda Y
Hum Pathol; 2020 Jul; 101():31-39. PubMed ID: 32360490
[TBL] [Abstract][Full Text] [Related]
5. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
6. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
Front Immunol; 2022; 13():953721. PubMed ID: 35979371
[TBL] [Abstract][Full Text] [Related]
7. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
9. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
10. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
Hahn AW; Kotecha RR; Viscuse PV; Pieretti AC; Wiele AJ; Jonasch E; Lee CH; Gao J; Zurita AJ; Shah AY; Campbell MT; Sharma P; Motzer RJ; Russo P; Wood CG; Tannir NM; Voss MH; Karam JA; Hakimi AA; Msaouel P
Eur Urol Focus; 2023 Sep; 9(5):734-741. PubMed ID: 36863962
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
14. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
15. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?
Adashek JJ; Zhang Y; Skelton WP; Bilotta A; Chahoud J; Zemp L; Li J; Dhillon J; Manley B; Spiess PE
Front Oncol; 2020; 10():627025. PubMed ID: 33643921
[TBL] [Abstract][Full Text] [Related]
16. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features.
Fontes-Sousa M; Calvo E
Cancer Treat Rev; 2022 Apr; 105():102374. PubMed ID: 35303549
[TBL] [Abstract][Full Text] [Related]
17. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Buonerba C; Dolce P; Iaccarino S; Scafuri L; Verde A; Costabile F; Pagliuca M; Morra R; Riccio V; Ribera D; De Placido P; Romeo V; Crocetto F; Longo N; Imbimbo C; De Placido S; Di Lorenzo G
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050629
[No Abstract] [Full Text] [Related]
20. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
